Achiko AG (Achiko AG) EBITDA Margin % : 0.00% (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Achiko AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Achiko AG's EBITDA for the six months ended in Jun. 2022 was $-1.98 Mil. Achiko AG's Revenue for the six months ended in Jun. 2022 was $0.00 Mil. Therefore, Achiko AG's EBITDA margin for the quarter that ended in Jun. 2022 was 0.00%.

Achiko AG EBITDA Margin % Historical Data

The historical data trend for Achiko AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG EBITDA Margin % Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

EBITDA Margin %

-103.09

-505.17

-13,379.37

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EBITDA Margin %	Get a 7-Day Free Trial			-185.97	-8,799.04	-12,247.37	-15,100.00	-

Competitive Comparison of Achiko AG's EBITDA Margin %

For the Health Information Services subindustry, Achiko AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achiko AG's EBITDA Margin % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Achiko AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Achiko AG's EBITDA Margin % falls into.

Achiko AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Achiko AG's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-8.429	/	0.063
	=	-13,379.37 %

Achiko AG's EBITDA Margin % for the quarter that ended in Jun. 2022 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	-1.975	/	0
	=	%

Achiko AG (OTCPK:ACHKF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Achiko AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Achiko AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (Achiko AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (OTCPK:ACHKF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.